Please assess the completion status of the following clinical trial:

Trial Title: Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. DBMD as determined by either a skeletal muscle biopsy demonstrating absence or lack of dystrophin, and/or genetic testing showing a mutation in the dystrophin gene predictive of DBMD, as well as a consistent physical examination~2. Male gender~3. Age greater than or equal to 18 years~4. Cardiac dysfunction with ejection fraction less than or equal to 50% as determined by echocardiogram, cardiac MRI, or multi-gated acquisition (MUGA) scan~5. On a stable dose of ACE-inhibitor or angiotensin receptor blocker (ARB) for at least 3 months; beta-adrenergic receptor blockers and glucocorticosteroids are not required but if used, a stable dose for at least 3 months is required.~6. Ability of the subject or legal guardian to provide informed consent~7. Ability to adhere with study follow-up~8. Willingness to abstain from food and alcohol for 8 hours prior to FMD~Exclusion Criteria:~1. Use of nitrates or alpha-adrenergic receptor blockers~2. Known intolerance or allergy to sildenafil, or a history of any severe allergic or anaphylactic reactions~3. Any medical or psychosocial condition, which, in the view of the study investigator, makes study participation inadvisable~4. Known hereditary retinal disorder such as retinitis pigmentosa~5. History of priapism or conditions that may predispose to priapism such as sickle cell anemia, multiple myeloma, or leukemia~6. Bleeding disorders~7. Active tobacco use~8. Chronic atrial fibrillation or frequent arrhythmia that would result in an irregular pulse~9. Factors that would preclude obtaining an MRI study - (e.g. implantable pacemaker or cardioverter-defibrillator; body habitus cannot fit into scanner)~10. Systolic blood pressure (SBP) less than 85 mmHg at baseline evaluation~11. Chronic kidney disease stages 4 and 5: GFR\< 30 mL/min/1.73 m2 as determined by serum cystatin C level and the equation eGFRcys = 76.7 x (serum cystatin C-1.18)~12. Current use of sildenafil.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Revatio (sildenafil) (Type: EXPERIMENTAL): This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
- Placebo (Type: OTHER): This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.

Based on this trial design, predict the completion outcome and termination type (if applicable).